Established in 1976 under the name of Biobrás, the Company initiated its activities with the production of animal insulin with technology developed through a joint venture with Eli Lilly. Biobrás became a listed company in the São Paulo’s Stock Exchange and 1983 the Company acquired the control of the joint venture. It expanded its market providing insulin to the Brazilian and foreign markets, being able to compete directly with global insulin producers Novo Nordisk, Sanofi-Aventis and Eli Lilly.

In the late 90’s, the Company co-developed a recombinant-DNA technology for human insulin production with the Universidade Federal de Brasília (Federal University of Brasília) and built an industrial scale plant for this purpose. In the early 2000’s, pharmaceutical player Novo Nordisk acquired Biobrás and, through a spin-off transaction, all technology, including patents, intellectual property, research staff and laboratory were transferred to a “new company” named Biomm S.A. From 2001 to 2012, Biomm S.A. (BOVESPA: BIOM3M) remained listed in São Paulo’s stock exchange and continued to invest in technology quality and efficiency improvements.

TMG Capital has identified and secured the opportunity to invest in the re-capitalization of Biomm S.A. and make it the sole producer of insulin in Brazilian territory. Nowadays, 100% of the product is imported and approximately ten million Brazilians need to use the product every day, making this project a matter of high relevance to the country. In this context, TMG joined BNDES, BDMG and Biomm’s founders to raise approximately R$ 400 million (equity and debt) to build a recombinant-DNA insulin plant.

Learn more about the company at

São Paulo Phone: 55 11 4064-5050

2011 TMG Capital. All rights reserved.